chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt received 3 doses of the Pfizer COVID-19 vaccine (initial 2 dose series and immunocompromised 3rd dose.  Received on 2/4/2021, 2/24/2021, and 8/18/2021 respectively).  Pt still contracted COVID and was ill enough to be hospitalized.  Symptom onset of 10/13/2021, tested positive 10/18/2021 and admitted to hospital.  **Acute hypoxic respiratory failure secondary to COVID-19 pneumonia: Patient with symptom onset 10/13/2021 with positive Covid test 10/18/2021.  Patient is up-to-date on SARS-CoV-2 mRNA vaccine series including recent booster dose, but notably patient is immunosuppressed on chronic immunosuppressive medications.  Patient with rapid respiratory decline, initially on room air, progressed rapidly to higher needs. Initial chest x-ray with bilateral opacities, right greater than left with progressive bilateral airspace opacities on repeat chest x-ray 10/20/2021. -Started on dexamethasone 6 mg daily on 10/18/2021, but with progressive respiratory decline, increased to 10 mg twice daily 10/20/2021. Decreased to 6mg twice daily, by mouth, on 10/27.  -Remdesivir initiated 10/18, completed 5-day course on 10/22/2021 -Continue baricitinib, started 10/20/2021 with progressive respiratory decline.  Plan for 14-day course or until discharge (whichever shorter) -prone positioning as tolerated -Continue supplemental O2.  If progressive O2 requirements, would likely need transition to PAP therapy, but not agreeable to intubation if needed for further respiratory decline. -Symptomatic therapies with as needed Tylenol, albuterol -CRP and D-dimer have down trended.  No ongoing monitoring needed at this time. -Saline nebulizer treatments, Aerobika, and guaifenesin for mucolytics
Itchy throat; Hives; This spontaneous case was reported by a consumer and describes the occurrence of THROAT IRRITATION (Itchy throat) and URTICARIA (Hives) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer (Dose 2) and Pfizer (Dose 1). Past adverse reactions to the above products included Vaccination adverse reaction with Pfizer and Pfizer.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced THROAT IRRITATION (Itchy throat) and URTICARIA (Hives). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, THROAT IRRITATION (Itchy throat) and URTICARIA (Hives) outcome was unknown.            No concomitant medication was provided by the reporter.  It was reported that patient did not have a choice so chanced it and got Pfizer the 1st two times. It was not great but no overt allergic reaction. For the booster patient did moderna and took Benadryl. Again, not great but no face swelling. Just itchy throat and a few hives.
Development of lichen planus on tongue. Treatment still on-going.  Symptions are a rough, white texture on surface of tongue, a burnt-tongue sensation with a constant pain level (scale of 1-10, 10 being the worst) is 5.  Unsuccessfully treated with the following:  dexamethasone rinse, prednisolone rinse, and clobetasol gel.  Currently trying prednisone tablets and salt water rinses.
A non-serious spontaneous report of administration of expired product was received from a pharmacist concerning a five-year-old female. Neither past medical history nor concomitant medications were reported for this patient. The FLUMIST expired on 02-Jan-2011. On 05-Jan-2011, the patient received the expired FLUMIST. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved. Additional information was received on 24-Mar-2011 which confirmed that the patient did not report any adverse events following administration of expired FLUMIST. This information was incorporated into the narrative.
Information has been received from a pharmacy student concerning an adult female patient who was vaccinated with four doses of ATTENUVAX vaccine(Enders-Edmonston) and is seronegative for measles titers. the patient sought medical attention via telephone. No product quality complaint was involved. No further information is available.
No adverse effects reported; Medical assistant reports concurrent administration of VARIVAX and PROQUAD to patient; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. No information was provided regarding the patient's medical history, current conditions, concomitant medications, drug reactions and allergies.  On 12-AUG-2019, the patient was vaccinated concurrently with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA)(PROQUAD) with lot number S005880 and expiration date on 25-AUG-2020, for prophylaxis (dose, dose number, route of administration and anatomical injection site were not reported); and varicella virus vaccine live (oka/merck) (VARIVAX) (lot No. R017945 has been verified to be a valid lot number for varicella virus vaccine live (oka/merck), expiration date reported as 24-JUL-2020, but upon internal validation established as 24-JUN-2020) for prophylaxis (dose, dose number, route of administration and anatomical injection site were not reported) (inappropriate schedule of product administration). No adverse effects reported.
Headache; Fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), PYREXIA (Fever) and CHILLS (Chills) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced HEADACHE (Headache), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, HEADACHE (Headache), PYREXIA (Fever) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. Treatment medications were unknown.
AFTER RECEIVING THE VACCINE, SHE STARTED HAVING DIFFICULTY BREATHING. ONSITE EMS/PHYSICIAN RESPONDED. VITALS ARE BELOW. EMS WANTED TO TRANSFER HER TO EMERGENCY ROOM BUT SHE REFUSED AND WENT HOME AGAINST MEDICAL ADVICE.
pt recv vax & more than a month later,pt devel a morbilliform rash  that was itchy w/assoc adenopathy,& presented to MD;lesions persisted @ the time of report,which was about 3 wk p/they had appeared;
About 2 weeks after my first dose I experienced extreme chest pain and pain in my left arm. I?ve never had these pains before, and it was an extremely sharp pain as though I was about to have a heart attack.  I reported these to my doctor and they ran an ekg with no serious findings. I refused to get my second dose of the moderna vaccine. Since those initial pains, my chest pain is now minor pain. The pain comes and goes periodically.
Initial and follow up information has been received from a physician concerning a 13 month old white female with developmental delay who on 10/12/04 was vaccinated SC in the left arm with her first dose of MMR (lot # 648473/0313P). Concomitant therapy included varicella virus vaccine live, influenza virus split virion 3v vaccine inactivated, and polymyxin B sulfate (+) trimethoprim. On 11/3/04, the patient developed acute parotitis with swelling in the left gland. The physician reported that approximately 12 days ago the patient received MMR, and that she presented with sudden onset of swelling of left cheek. It was also reported that the whole left side of her face was swollen, and that there was a firm induration and a soft, puffy area. There was no fever or change in level of consciousness. At the time of the report, the patient had not yet recovered. The physician felt that acute parotitis was related to MMR. There was no product quality complaint involved. No further information is available.
myocarditis; Chest pain; This is a spontaneous report from two contactable consumers (one is patient himself and the other one is patient's wife). A 35-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 07May2021 15:30 (Batch/Lot Number: EW 0171; Expiration Date: Aug2021) as 2nd dose, single for covid-19 immunisation, at a public Health Department. The vaccine was not administered at Military Facility. No additional Vaccines Administered on Same Date of the Pfizer Suspect. The patient's medical history included known allergies: Sulfa. No family Medical History Relevant to events. There were no concomitant medications. There was no other products. The patient did not receive any other medications within 2 weeks of vaccination. For historical vaccine, there was no prior vaccinations within 4 weeks aside from first dose: bnt162b2, dose 1 intramuscular administered in Arm Left on 16Apr2021 15:30 (Batch/Lot Number: ER 8737; Expiration Date: Aug2021) (at the age of 35-year-old) as 1st dose, single for covid-19 immunisation. The facility of vaccination was Other no AE. On 08May2021 02:00, the patient experienced chest pain. The event chest pain resulted in Emergency room/department or urgent care, hospitalization, and was life threatening illness (immediate risk of death from the event). On 13May2021, the patient's wife reported that her husband was in the hospital with myocarditis onset from 11May2021(also reported as three days after receiving his second dose of the vaccine). The patient was admitted to the hospital at 02:00 on Tuesday 11May2021, he was still in the hospital by the time of reporting. Also reported that the event myocarditis required Emergency Room visit. A lot of testing were done such as cardiac ultrasounds, several electrocardiogram (EKG)s and electrocardiogram (ECG)s, nuclear cardiac wall motion test or some kind of nuclear test she is unsure of the name, chest x-rays three times, several blood works, his troponin levels (heart enzyme) was critical. The patient did not have COVID prior to vaccination. The patient had been tested post vaccination, COVID test type post vaccination was Nasal Swab on 11May2021, result was Negative. The patient had full work up less than a year ago and everything came back completely normal (In 2020). Therapeutic measures were taken as a result of events chest pain and myocarditis. The patient was treated with medication and he had to get a wearable defibrillator called Life Vest. They have him on a blood thinner, carvedilol, and entresto. The outcome of the events was not recovered.
Developed "bumps" on face, neck as of day after vaccination. Persisted for 1 week; probably congruent with "hives".
I have skin rashes all in my body and they are increasing exponentially. I had phone call with the doctor and I have provided him with the photos of my body (hands, chest, back, face etc.) places where I have skin rashes, redness, infection, allergy due to vaccine.
Pt. was seen here on 1-4-08 for school exam, PPD & immun update.  Exam was normal.  Varicella was given in R upper arm/SQ.  Pt. came back in for PPD reading on 1-7-08.  PPD reading was 4 mm.  Upper arm had a large, red area reaching from shoulder to almost elbow w/ firm round area at site almost 3 inches wide.  Pt. did not appear sick.  No fever.
FULLY VACCINATED PATIENT ADMITTED TO THIS FACILITY 7/11/2021 WITH HEADACHE AND MYALGIAS AND SOB
Ptient developed hair loss after receiving a form of GARDASIL.; This spontaneous report has been received from a nurse through a company representative, and refers to an approximately 36-year-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, and previous drug reactions or allergies were not reported.   On an unknown date, when the patient was an approximately 14-15 years old, she was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) or Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (The reporter was not sure which vaccine was administered) injection, administered intramuscular (strengths exact, dosages, vaccination schemes frequency, anatomical sites of injection, lots number, and expiry dates were not reported) as prevention of human papillomavirus infection HPV (prophylaxis).  On an unspecified date (approximately between 2001 and 2002) the patient experienced hair loss (alopecia). No treatment was received. Subsequently, on an unknown date, the patient recovered from alopecia.   The causality assessment between the event and the suspect vaccine was not provided.
Information has been received from a medical assistant referring to a 4 month old male patient. The patient's medical history and concomitant therapy were not reported. At the time of the vaccination, the patient had an upper respiratory tract infection. On 06-AUG-2018, the patient was vaccinated with improperly stored ROTATEQ (lot # N030176, expiry date: 17-JUN-2019; dosing details unknown) orally for prophylaxis in a public health clinic/hospital using public funds (Incorrect product storage). Other suspect therapies administered on the same day included PREVNAR 13 (lot # T94424) in the right thigh and PENTACEL (lot #C5461AA) in the left thigh. The patient was previously administered with 1 dose of the vaccines. No prescription drug treatment was required for the experience. The patient did not receive any reverse reactions to the vaccine. The vaccine was stored at a temperature of 0 Celsius (C) degree to 1 C degree for 41 hours, below 0 C degree (-0.01) for 27 hours and between 9 C degree to 25 C degree (16.4 C) for 12 hours 30 minutes. Previous temperature excursion were 0 C degree to 1 C degree for 27 hours. Data logger was involved. No adverse effect reported. No product quality complaint (PQC) was involved. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1808USA003706.
Patient developed rash 10 minutes after getting  Pfizer  . She had spots on both arms and the chest. She took Benadryl and the rash went away about 30 minutes after the shot.
Tinnitus, ear ringing, noise, hissing sound appeared in the week following the #1 vax. Reported to my primary care provider on 1/22.  Prescribed antibacterial regimen. Condition not resolved.  Referred to Ear, Nose & Throat specialist confirmed diagnosis.
Flu; Vaccination failure; This is a spontaneous case, reported by other health professional to VAERS and initially received on 28-Jan-2019, concerning a 05-year-old, male child patient.  The patient's current condition included seizure (since an early 2015). It was reported that, no other chronic conditions were noted. The patient's concomitant medication included Keppra (levetiracetam) for seizure.  On 09-Oct-2018, the patient was administered Flucelvax QIVc [influenza vaccine, subunit influenza virus vaccine polyvalent, cell-culture-derived, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 252664 and expiry date: 30-Jun-2019] for active immunization against influenza disease.  On 24-Jan-2019, 3 months and 15 days after vaccination, the patient was diagnosed with flu by the pediatrician (explicitly coded as vaccination failure). The patient was treated with Tamiflu (oseltamivir phosphate).  On an unspecified day, the patient made a visit to adverse event (reported as A and E) department but was not hospitalized.  On 26-Jan-2019, the patient had recovered from the event.  The reporter assessed the case as non-serious.  Significant follow up received from the reporter on 04-Feb-2019: The start date and stop date of the event flu was added. The company causality for the event flu was changed from unassessable' to related'. The treatment drug Tamiflu' was added with the start date: 24-Jan-2019. Added new event vaccination failure in the event tab. It was confirmed that, the patient was okay and had no symptoms to report. Also reported that, the patient visited an adverse event department, but was not hospitalized. The permission to contact patient was given. The narrative was amended accordingly.  Follow up received from other health professional (nurse) on 18-Feb-2019: The start date (early 2015) of the current condition seizure was added in the patient tab. The concomitant medication Keppra for patient's current condition seizure was added in the product tab. The narrative was amended accordingly.; Reporter's Comments: A 05-year-old male patient experienced flu 3 months 15 days after Flucelvax QIV vaccination (coded to influenza & vaccination failure). Considering the fact that vaccine needs minimum 2-3 weeks to provide immune protection against influenza, vaccination failure and causal role of suspect vaccine for the event flu cannot be ruled out and was assessed as related to suspect vaccine. Further assessment will be done upon receipt of new information.The company assessed the event 'flu' as serious (medically significant).
Heavy anovulatory bleeding 8 days after the end of my regular cycle. I am not on birth control , I track my periods every month & am freakishly regular. Regular period: January 4-8, 2022- New bleeding: January 16, 2022-current.
Pain at injection site for three days following the vaccine. Pain and swelling in lymph node under armpit lasting for one week after receiving vaccine.
pt was seen in ER by MD;mom stated pt's eyes rolling up & back of head & eyebrows were twitching,trembling a little bit;was sobbing,was fussy;pt was febrile in ER:CBC,chem 10,blood cult,UA,urine cult,CXR
Dx Headache  ? Sore Throat ? Fever ? Eye Problem  ? Cough ? Covid-19 Screening  ? Nasal Congestion   Sore throat  Acute nonintractable headache, unspecified headache type  Fever, unspecified fever cause  Cough  Nasal congestion with rhinorrhea  At increased risk of exposure to COVID-19 virus   Conjunctivitis due to COVID-19  Vagal reaction
This case was reported by a nurse and described the occurrence of inappropriate preparation of medication in a patient who received ROTARIX. On an unknown date, the patient received ROTARIX at an unknown dose. On an unknown date, an unknown time after receiving ROTARIX the patient experienced inappropriate preparation of medication. On an unknown date, the outcome of the inappropriate preparation of medication was unknown. Additional information received: A dose of ROTARIX diluent was given without the active drug in the diluent. The caller refused to give any information except the street address.
Stroke; recall/memory problems; could no longer speak; A spontaneous report was received from consumer (patient's husband) for a 90-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced stroke and could no longer speak, stroke and recall/memory problems  The patient's medical history was not provided. Concomitant product use included enalapril maleate, hydrochlorothiazide, furosemide, potassium chloride extended release, clopidogrel and apixaban.  On 04-Feb- 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 020M20A) intramuscularly on left non dominant deltoid for prophylaxis of COVID-19 infection. After receiving the vaccine on an unspecified date in 2021 in the middle of the night, the patient woke up and could no longer speak. The patient was taken to the hospital and had a stroke. The patient was admitted for 2 days and 2 nights. The patient was not able to recall and have memory problems at the time of this report.  Treatment information was not provided.  Action taken with mRNA-1273 was unknown.  The outcome of the events, could no longer speak and stroke were  unknown and outcome for recall/memory problems was not recovered.; Reporter's Comments: Although a temporal association exist, based on the lack of critical details such as the patient's medical history and other relevnt information for accurate assessment is lacking.  Concomitant medications is suggestive of underlying cardiac disease.  Additional information have been requested.
This spontaneous report as received from a health care worker refers to a 4 year old patient of unknown gender. On 23-NOV-2009, the patient was vaccinated with a dose of M-M-R II (Lot number, expiry date were not reported), 0.5 milliliter (ml) subcutaneous. On 16-SEP-2013, the patient was vaccinated with a dose of M-M-R II (Lot number, expiry date, route and dose were not reported), that had an unsupported temperature excursion on 13-SEP-2013. No adverse effects reported. Additional information has been requested.
Hives, noted in face, scalp, hands, knees, feet.  Currently treated with steroids and anti-histamines for 4 days, with mild improvement.
Temp to 102, with R shoulder swelling and pain X 3d. Seen at ER and started on AbX. Currently afebrile and improving recovering.
Started noticing a intermittent bilateral hearing loss, then all of a sudden  loss hearing on the right ear.
All over flushed feeling and generalized tingling.  Blood pressure elevated on assessment: 9:46am- 179/111, 9:48am- 168/120, 10:48am- 129/77, 10:00am- 151/104.    started within 5 minutes post-vaccine lasting approximately 40 minutes
Headache, Fever, NauseaVomiting, General Symptoms:  Chills, fever, headaches, fatigue,  nausea, diarrhea. Narrative:  Other Relevant History:
The patient states she asked for the Flu vaccine and not the COVID-19 vaccine.  Pfizer Comirnaty 2023-2024 was administered in error.
Symptoms started roughly five hours after receiving the vaccine. It began with cold sweats, where I was shivering but sweating. Then I began experiencing nausea overnight coupled with a headache.
had vax 5AUG93; 12AUG93 had diarrhea & fever never completely recoved; 27AUg93 had lt arm pain radiating to neck; & loss of strength lt arm; also reports irregular heart rate, but has prolapsed mitral valve; MD dx ?GBS;
Company was notified on 6/7/21 by an organization that a dose of the Moderna Vaccination was inadvertently given to a 17 year old.
Presented to urgent care on 3/20/21 with shortness of breath, fever, chills and body aches. Was referred to ED due to O2 sat of 86%.  Was started on supplemental oxygen in ED and admitted to hospital.
I woke up from sleeping with one big cough. I felt chest pressure and some pain, trouble breathing, nausea but did not vomit. My wife called 911 and I was admitted to the hospital.
1st shot on 4/29/21 reactivated almost dormant Bullous Pemphigoid condition in the form of severe blisters on 5/7/21. Blisters developed in the vicinity of virtually healed wounds from a bicycle accident 2 months prior. As blisters worsened, on 5/19/21 my dermatologist prescribed a high dose regimen of Prednisone and Minocycline. Three weeks since onset, my condition is slowly improving with treatment. Also, on 5/11/21, my heart rate elevated significantly causing me to nearly faint. My normal resting pulse is 60-70 bpm, and since 5/11/21, it has been between 97-103 bpm.  An EKG on 5/25/21 identified Long QT Syndrome which I've never had before. No change in medications recommended. Monitoring from home.
The day after receiving my 2nd COVID shot I had experienced whole body aches for a period of approximately 12-14 hours
Face started swelling, hives noted around eyes, patient reported unable to breathe, throat closing. Epinephrine was administered with resolution of symptoms. Patient was observed for one hour by pediatrician for return of symptoms, and she did again begin to have hives and some throat swelling sensation, Benadryl was administered and symptoms resolved. She was prescribed an Epi-pen, and went home with no further symptoms.